SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
26 Jul 2017
SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM)
SkylineDx Researchers Publish Data Demonstrating Utility of SKY92 as Prognostic Tool in Multiple Myeloma (MM) Clinical Lymphoma, Myeloma and Leukemia Paper Validates Use of SKY92 and its Combination with International Staging System (ISS) ...
Upcoming Events
13 Sep 2017 - 16 Sep 2017, Houston, TX, USA
Society of Hematologic Oncology - 2017 Annual Meeting
06 Oct 2017 - 07 Oct 2017, San Francisco, CA, USA
NCCN 11th Annual Congress: Hematologic Malignancies
09 Dec 2017 - 12 Dec 2017, Atlanta, GA, USA
American Society of Hematology - 59th Annual Meeting & Exposition